OOIR: Observatory of International Research

Papers

(The H4-Index of Lancet Rheumatology is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Real-world evidence for prehospital COVID-19 treatment in systemic autoimmune rheumatic disease	792
Molecular signature-based decision making in the era of targeted therapies for systemic lupus erythematosus	772
COVID-19 vaccine-induced T-cell responses in patients with rheumatoid arthritis: preferential induction by ChAdOx1	278
A disseminated gonococcal infection with spinal locations	186
Thrombotic microangiopathy as a presentation of anti-synthetase syndrome	173
Brachial plexopathy: an unusual manifestation of Takayasu arteritis	147
Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study	133
Research in Brief	133
From phenotype to pathophysiology—placing rheumatic diseases in an immunological perspective	131
Acceptability of the COVID-19 vaccine among patients with chronic rheumatic diseases and health-care professionals: a cross-sectional study in 19 Arab countries	113
Can contextual factors improve clarity of the results from clinical trials of low back pain?	112
Women in rheumatology in Africa	110
Reigniting the burnt-out health-care workforce	99
Dual JAK and ROCK inhibition with CPL'116 in patients with rheumatoid arthritis with inadequate response to methotrexate: a randomised, double-blind, placebo-controlled, phase 2 trial	90
1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial	90
Three-dimensional, in-vitro approaches for modelling soft-tissue joint diseases	87
Pathways driving tendinopathy and enthesitis: siblings or distant cousins in musculoskeletal medicine?	85
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial	82
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?	81
Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands	73
Biological disease-modification in axial spondyloarthritis: insights from MRI	73
Surgical microdiscectomy versus transforaminal epidural steroid injection in patients with sciatica due to lumbar disc herniation	70
Early-stage Dupuytren's disease treatment; a promising next step?	66
Interleukin-5 inhibition in eosinophilic granulomatosis with polyangiitis: time for another approach?	62
Juvenile systemic lupus erythematosus presenting as retinal vasculitis	58

Pausing drugs and spacing vaccines: an open question – Authors' reply	56
Artificial intelligence and high-dimensional technologies in the theragnosis of systemic lupus erythematosus	54
Sex as a predictor of clinical phenotype and determinant of immune response in IgG4-related disease: a retrospective study of patients fulfilling the American College of Rheumatology–European League A	53
Preload deficiency as a treatable cause of fatigue and exercise intolerance in SLE	52
Pain in clinical trials for knee osteoarthritis: estimation of regression to the mean	52
Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial	51
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis	49
Immunity after COVID-19 vaccinations in immunocompromised patients with psoriasis	45
Composite endpoints for Sjögren's Syndrome	45
Reclassifying ANCA-associated vasculitis: a focus on kidney disease	44
Research in Brief	44
Patient-reported outcomes with anifrolumab in patients with systemic lupus erythematosus	44
Outdoor temperatures and Raynaud's phenomenon in patients with systemic sclerosis	43
Assessing glucocorticoid toxicity: are the measures sensitive enough?	43
Proof-of-concept studies in axial spondyloarthritis: there are no shortcuts	42
Addition of aerobic physical activity to resistance exercise for hip osteoarthritis (PHOENIX): a randomised comparative effectiveness trial	42
First-line biological versus conventional synthetic disease-modifying antirheumatic drug therapy in adult-onset Still's disease: a multicentre, retrospective, propensity weighted cohort study	41
Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis	41
Biosimilars and the era of interchangeability	41
The association of outdoor temperature and self-reported Raynaud's phenomenon severity among people with systemic sclerosis: a Scleroderma Patient-centered Intervention Network Cohort study	41